<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1406" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1406/" /><meta name="ncbi_pagename" content="Lymphoproliferative Disease, X-Linked - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Lymphoproliferative Disease, X-Linked - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Lymphoproliferative Disease, X-Linked" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/06/30" /><meta name="citation_author" content="Kejian Zhang" /><meta name="citation_author" content="Emily Wakefield" /><meta name="citation_author" content="Rebecca Marsh" /><meta name="citation_pmid" content="20301580" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1406/" /><meta name="citation_keywords" content="Duncan Disease" /><meta name="citation_keywords" content="XLP" /><meta name="citation_keywords" content="XLPD" /><meta name="citation_keywords" content="Duncan Disease" /><meta name="citation_keywords" content="E3 ubiquitin-protein ligase XIAP" /><meta name="citation_keywords" content="SH2 domain-containing protein 1A" /><meta name="citation_keywords" content="SH2D1A" /><meta name="citation_keywords" content="XIAP" /><meta name="citation_keywords" content="Lymphoproliferative Disease, X-Linked" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Lymphoproliferative Disease, X-Linked" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Kejian Zhang" /><meta name="DC.Contributor" content="Emily Wakefield" /><meta name="DC.Contributor" content="Rebecca Marsh" /><meta name="DC.Date" content="2016/06/30" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1406/" /><meta name="description" content="X-linked lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2. XLP1 is characterized predominantly by one of three commonly recognized phenotypes:" /><meta name="og:title" content="Lymphoproliferative Disease, X-Linked" /><meta name="og:type" content="book" /><meta name="og:description" content="X-linked lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2. XLP1 is characterized predominantly by one of three commonly recognized phenotypes:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1406/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/x-lpd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1406/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE894E52E040A3E100000000056E0272.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1406_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1406_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/lds/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hnpcc/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1406_"><span class="title" itemprop="name">Lymphoproliferative Disease, X-Linked</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Duncan Disease, XLP</div><p class="contrib-group"><span itemprop="author">Kejian Zhang</span>, MD, MBA, <span itemprop="author">Emily Wakefield</span>, MS, and <span itemprop="author">Rebecca Marsh</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1406_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1406_ai__"><div class="contrib half_rhythm"><span itemprop="author">Kejian Zhang</span>, MD, MBA<div class="affiliation small">Associate Professor of Pediatrics, Division of Human Genetics<br />Cincinnati Children&#x02019;s Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@gnahz.naijek" class="oemail">gro.cmhcc@gnahz.naijek</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Emily Wakefield</span>, MS<div class="affiliation small">Genetic Counselor, Division of Human Genetics<br />Cincinnati Children&#x02019;s Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@dleifekaw.ylime" class="oemail">gro.cmhcc@dleifekaw.ylime</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Rebecca Marsh</span>, MD<div class="affiliation small">Assistant Professor of Pediatrics, Division of Bone Marrow Transplantation and Immune Deficiency<br />Cincinnati Children&#x02019;s Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@hsram.acceber" class="oemail">gro.cmhcc@hsram.acceber</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 27, 2004</span>; Last Update: <span itemprop="dateModified">June 30, 2016</span>.</p><p><em>Estimated reading time: 25 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="x-lpd.Summary" itemprop="description"><h2 id="_x-lpd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2. XLP1 is characterized predominantly by one of three commonly recognized phenotypes:</p><ul><li class="half_rhythm"><div>Inappropriate immune response to Epstein-Barr virus (EBV) infection leading to hemophagocytic lymphohistiocytosis (HLH) or severe mononucleosis</div></li><li class="half_rhythm"><div>Dysgammaglobulinemia</div></li><li class="half_rhythm"><div>Lymphoproliferative disease (malignant lymphoma)</div></li></ul><p>XLP2 is most often characterized by HLH (often associated with EBV), dysgammaglobulinemia, and inflammatory bowel disease. HLH resulting from EBV infection is associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Dysgammaglobulinemia is typically hypogammaglobulinemia of one or more immunoglobulin subclasses. The malignant lymphomas are typically B-cell lymphomas, non-Hodgkin type, often extranodal, and in particular involving the intestine.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of XLP is established in a male by identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SH2D1A</i> (associated with XLP1) or <i>XIAP</i> (associated with XLP2) on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment of XLP-related HLH is similar to that of other life-threatening genetic hemophagocytic disorders and includes immunosuppressive agents such as steroids and etoposide or anti-thymocyte globulin. Rituximab therapy may also be considered when HLH is associated with EBV infection. Hypogammaglobulinemia is treated with IVIG replacement therapy. Lymphoma is treated with standard chemotherapy appropriate to the tumor. Inflammatory bowel disease is treated with immunosuppression. For all clinical phenotypes of XLP, the only curative treatment is allogeneic hematopoietic cell transplantation (HCT), which should be considered in most individuals as early as possible.</p><p><i>Prevention of primary manifestations:</i> Boys with known or suspected XLP and hypogammaglobulinemia should receive regular intravenous (IV) IgG replacement therapy every three to four weeks until definitive treatment can be provided.</p><p><i>Surveillance:</i> Blood should be monitored by EBV-<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> for evidence of EBV infection if symptoms of infection and/or HLH develop; blood counts, hepatic profiles, coagulation studies, and inflammatory markers should be monitored as needed based on clinical status for early evidence of HLH; IgG levels should be monitored as needed based on clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p><i>Agents/circumstances to avoid:</i> Individuals with XLP who come into contact with EBV are at risk until curative treatment with allogeneic HCT has been performed. Individuals are also at risk of developing HLH or inflammatory problems with other infections.</p><p><i>Evaluation of relatives at risk:</i> Molecular genetic testing of at-risk sibs and other relatives for the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> facilitates early diagnosis and treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>XLP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. The risk to the sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the mother: if the mother is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, the chance of transmitting the <i>SH2D1A</i> and <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy is 50%. Male sibs who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; female sibs who inherit the pathogenic variant will be heterozygotes and will typically not be affected (in rare cases, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females may be symptomatic due to skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>). Carrier testing of at-risk female relatives is most informative if the pathogenic variant has been identified in the proband. Prenatal testing is possible for pregnancies at increased risk if the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pathogenic variant is known.</p></div></div><div id="x-lpd.Diagnosis"><h2 id="_x-lpd_Diagnosis_">Diagnosis</h2><div id="x-lpd.Suggestive_Findings"><h3>Suggestive Findings</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> lymphoproliferative disease (XLP) <b>should be suspected</b> in a male with any of the following clinical presentations or laboratory features.</p><div id="x-lpd.Clinical_Presentations"><h4>Clinical Presentations</h4><p>The following are suggestive of XLP:</p><ul><li class="half_rhythm"><div>Fatal or near-fatal Epstein-Barr virus (EBV) infection / severe fulminant infectious mononucleosis</div></li><li class="half_rhythm"><div>Hemophagocytic lymphohistiocytosis (HLH) resulting from EBV or other viral illness (e.g., influenza, cytomegalovirus, adenovirus, varicella), especially in childhood or adolescence; or HLH without an identifiable trigger</div></li><li class="half_rhythm"><div>Dysgammaglobulinemia</div></li><li class="half_rhythm"><div>Lymphoproliferative disease (malignant lymphoma) (XLP1)</div></li><li class="half_rhythm"><div>Inflammatory bowel disease (XLP2)</div></li><li class="half_rhythm"><div>Family history of one or more maternally related males with an XLP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></div></li></ul></div><div id="x-lpd.Laboratory_Features"><h4>Laboratory Features</h4><p>Males with XLP do not show any uniform abnormalities on standard immunologic testing; however, the following may be seen:</p><ul><li class="half_rhythm"><div class="half_rhythm">Variably decreased or increased numbers of lymphocyte subsets including decreased or increased T cells, B cells, and NK cells. HLH may be associated with T-cell expansion.</div><div class="half_rhythm">Note: (1) Males with XLP1 have absent invariant natural killer T cells (iNKT cells). (2) Males with XLP2 can have normal or decreased iNKT cell populations [<a class="bk_pop" href="#x-lpd.REF.marsh.2009.116">Marsh et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Impaired T-cell restimulation-induced cell death (males with XLP1) or increased susceptibility to T-cell restimulation-induced cell death (XLP2)</div></li><li class="half_rhythm"><div class="half_rhythm">Impaired 2B4-mediated cytotoxicity (XLP1)</div></li><li class="half_rhythm"><div class="half_rhythm">Impaired NOD2 signaling (XLP2)</div></li></ul><p><b>Acute EBV infection</b></p><ul><li class="half_rhythm"><div>EBV detection by <a class="def" href="/books/n/gene/glossary/def-item/polymerase-chain-reaction/">polymerase chain reaction</a> (<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>; preferred method)</div></li><li class="half_rhythm"><div>Positive heterophile antibodies or monospot testing</div></li><li class="half_rhythm"><div>Detection of EBV-specific IgM antibodies</div></li><li class="half_rhythm"><div>Atypical lymphocytosis on peripheral blood smear with expansion of CD8 T cells</div></li></ul><p><b>HLH / fulminant infectious mononucleosis</b></p><ul><li class="half_rhythm"><div>Markedly elevated liver transaminases and/or liver dysfunction/coagulopathy, hypofibrinogenemia</div></li><li class="half_rhythm"><div>Inverted CD4:CD8 ratio in peripheral blood</div></li><li class="half_rhythm"><div>Hemophagocytosis on bone marrow biopsy or in other tissues (e.g., CSF, lymph node)</div></li><li class="half_rhythm"><div>Cytopenias</div></li><li class="half_rhythm"><div>Splenomegaly</div></li><li class="half_rhythm"><div>Elevated plasma levels of soluble IL-2 receptor alpha</div></li><li class="half_rhythm"><div>Hypertriglyceridemia</div></li><li class="half_rhythm"><div>Hyperferritinemia</div></li></ul><p><b>Dysgammaglobulinemia.</b> Decreased levels of one or more immunoglobulin subclasses, most frequently manifest by low serum concentration of IgG, with variable serum concentrations of IgM and/or IgA that may also sometimes be abnormally increased</p></div></div><div id="x-lpd.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Because bone marrow transplantation becomes an option for acutely ill males if an <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be used early in the investigation of a male with the following:</p><ul><li class="half_rhythm"><div>A severe EBV (or other virus) infection</div></li><li class="half_rhythm"><div>Hemophagocytic lymphohistiocytosis (HLH)</div></li><li class="half_rhythm"><div>Immunodeficiency involving hypogammaglobulinemia of uncertain etiology</div></li><li class="half_rhythm"><div>Recurrence of a B-cell (typically non-Hodgkin) lymphoma</div></li></ul><p>The diagnosis of XLP <b>is established</b> in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with:</p><ul><li class="half_rhythm"><div class="half_rhythm">Low or absent SH2 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> protein 1A (SAP) expression by flow cytometry (XLP1) or low or absent XIAP expression by flow cytometry (XLP2), and normal perforin flow cytometric screening and CD107a flow cytometric screening (see <a href="#x-lpd.Differential_Diagnosis">Differential Diagnosis</a>);</div></li><li class="half_rhythm"><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SH2D1A</i> or <i>XIAP</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1406/table/x-lpd.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figxlpdTmoleculargenetictestingusedi" rid-ob="figobxlpdTmoleculargenetictestingusedi">Table 1</a>).</div><div class="half_rhythm">Note: Molecular genetic testing of <i>SH2D1A</i> or <i>XIAP</i> is recommended for all individuals with abnormal SAP and XIAP expression studies, and for individuals in whom clinical suspicion is high.</div></li></ul><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of XLP <b>is usually established</b> in a female proband who is symptomatic for XLP and has a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>XIAP</i> or <i>SH2D1A</i> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p><b>Molecular testing</b> approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div>In males with low or absent SH2 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> protein 1A (SAP) expression by flow cytometry, start with <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SH2D1A.</i> If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>SH2D1A</i> is performed.</div></li><li class="half_rhythm"><div>In males with low or absent XIAP expression by flow cytometry, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>XIAP</i> is performed first<i>.</i> If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>XIAP</i> is performed.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SH2D1A</i>, <i>XIAP</i>, and other genes of interest (see <a href="#x-lpd.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, and whole mitochondrial sequencing may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) fails to confirm a diagnosis in an individual with features of XLP.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="x-lpd.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in X-Linked Lymphoproliferative Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1406/table/x-lpd.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-lpd.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of XLP Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method</th></tr><tr><th headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_3" id="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></th><th headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_3" id="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SH2D1A</i></td><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">83%-97%&#x000a0;<sup>6</sup></td><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~75%&#x000a0;<sup>7</sup></td><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~25%&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XIAP</i></td><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12%&#x000a0;<sup>9</sup></td><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~85%</td><td headers="hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_x-lpd.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~15%&#x000a0;<sup>10</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="x-lpd.TF.1.1"><p class="no_margin">See <a href="/books/NBK1406/#x-lpd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="x-lpd.TF.1.2"><p class="no_margin">See <a href="#x-lpd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="x-lpd.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="x-lpd.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="x-lpd.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="x-lpd.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#x-lpd.REF.sumegi.2000.3118">Sumegi et al [2000]</a>, <a class="bk_pop" href="#x-lpd.REF.rigaud.2006.110">Rigaud et al [2006]</a></p></div></dd><dt>7. </dt><dd><div id="x-lpd.TF.1.7"><p class="no_margin">Sequence analysis of the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> and <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/<a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> boundaries identifies pathogenic variants in approximately 75% of <a class="def" href="/books/n/gene/glossary/def-item/obligate-carrier/">obligate carrier</a> females [<a class="bk_pop" href="#x-lpd.REF.stenson.2003.577">Stenson et al 2003</a>].</p></div></dd><dt>8. </dt><dd><div id="x-lpd.TF.1.8"><p class="no_margin">25% are predicted to have <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one or more exons or the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#x-lpd.REF.stenson.2003.577">Stenson et al 2003</a>].</p></div></dd><dt>9. </dt><dd><div id="x-lpd.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#x-lpd.REF.filipovich.2010.3398">Filipovich et al [2010]</a>. Note: The incidence of <i>XIAP</i> pathogenic variants in males who present with an HLH <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (as opposed to an XLP phenotype) is likely less than 10%.</p></div></dd><dt>10. </dt><dd><div id="x-lpd.TF.1.10"><p class="no_margin">15% are predicted to have <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one or more exons or the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#x-lpd.REF.stenson.2003.577">Stenson et al 2003</a>].</p></div></dd></dl></div></div></div></div></div><div id="x-lpd.Clinical_Characteristics"><h2 id="_x-lpd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="x-lpd.Clinical_Description"><h3>Clinical Description</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2.</p><div id="x-lpd.XLP1"><h4>XLP1</h4><p>The three most commonly recognized phenotypes are (<a class="figpopup" href="/books/NBK1406/table/x-lpd.T.clinical_phenotypes_of_sh2d1arel/?report=objectonly" target="object" rid-figpopup="figxlpdTclinicalphenotypesofsh2d1arel" rid-ob="figobxlpdTclinicalphenotypesofsh2d1arel">Table 2</a>):</p><ul><li class="half_rhythm"><div>An inappropriate immune response to EBV infection resulting in unusually severe and often fatal infectious mononucleosis or hemophagocytic lymphohistiocytosis (HLH) caused by EBV or other viral infection;</div></li><li class="half_rhythm"><div>Dysgammaglobulinemia; and</div></li><li class="half_rhythm"><div>Lymphoproliferative disease typically of B-cell origin.</div></li></ul><p>Clinical manifestations of XLP vary even among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members of the same family. Of note, some males with pathogenic variants in <i>SH2D1A</i> are asymptomatic and their long-term prognosis is not known.</p><p>Prior to EBV infection, most males with XLP1 appear generally healthy and do not have any characteristic clinical findings. In approximately 12% of males with XLP1, dysgammaglobulinemia precedes EBV infection, resulting in varying degrees of hypogammaglobulinemia and recurrent respiratory infections [<a class="bk_pop" href="#x-lpd.REF.sumegi.2000.3118">Sumegi et al 2000</a>].</p><p><a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al [2011]</a> reported mean age at death for individuals with an <i>SH2D1A</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as 11 years (range 2-69 years). Approximately 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males reached adulthood; of this group only one had hematopoietic cell transplantation (HCT). In this study, approximately 25% of surviving males were not receiving treatment; 60% received intravenous immunoglobulin (IVIG) only; and 12% were undergoing therapy for lymphoma. Mortality was related to HLH (70%), lymphoma (12%), myelodysplasia (6%), and complications of HCT (12%).</p><div id="x-lpd.T.clinical_phenotypes_of_sh2d1arel" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Clinical Phenotypes of <i>SH2D1A</i>-Related XLP (XLP1)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1406/table/x-lpd.T.clinical_phenotypes_of_sh2d1arel/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-lpd.T.clinical_phenotypes_of_sh2d1arel_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Individuals with XLP1 with This Phenotype</th><th id="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mortality Rate</th></tr></thead><tbody><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemophagocytic lymphohistiocytosis (HLH)</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.2%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">65.6%</td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dysgammaglobulinemia</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50.5%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13%</td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lymphoma</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">24.2%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fulminant infectious mononucleosis</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9.9%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">22.2%</td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15.4%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_sh2d1arel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28.6%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">From <a class="bk_pop" href="#x-lpd.REF.booth.2011.53">Booth et al [2011]</a></p></div></dd></dl></div></div></div><p><b>Fulminant infectious mononucleosis (FIM)/HLH associated with EBV.</b> The most commonly recognized presentation of XLP is a fatal or near-fatal EBV infection associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages [<a class="bk_pop" href="#x-lpd.REF.gaspar.2002.585">Gaspar et al 2002</a>]. Affected individuals typically have lymphadenopathy and hepatosplenomegaly with extensive parenchymal damage including fulminant hepatitis, hepatic necrosis, and profound bone marrow failure. Death is generally secondary to liver failure. Hemophagocytosis (phagocytosis identified by microscopy of intact or partially degraded blood cells) in bone marrow and/or CNS may also be seen in association with overwhelming EBV infection. Involvement of other organs may include the spleen ("white pulp" necrosis), heart (mononuclear myocarditis), and kidney (mild interstitial nephritis).</p><p><a class="bk_pop" href="#x-lpd.REF.booth.2011.53">Booth et al [2011]</a> found 65% of persons with XLP to be positive for EBV at diagnosis. In this group, the most common presentation of XLP was FIM/HLH, seen in 69% of individuals positive for EBV. In contrast, persons negative for EBV more typically presented with dysgammaglobulinemia (52%) or lymphoma (25%). HLH in the absence of EBV infection occurred in approximately 21%. The overall mortality rate of approximately 30% did not vary significantly between those who were positive for EBV and those who were not. Mortality was calculated based on whether the individual was alive or deceased at point of data collection. This time span varied between individuals from day 0 (presentation) to 148 months post transplant.</p><p>Note: In contrast, EBV infection in individuals who do not have XLP can occur as the well-recognized "infectious mononucleosis" (IM); in young infants, it can pass for a self-limited viral illness. IM may have an acute or insidious onset. Common manifestations are fever, malaise, and pharyngitis typically lasting one to four weeks. Variable lymphadenopathy and splenomegaly may persist for weeks or even months. A truncal macular eruption is observed in approximately 25% of individuals during the first two weeks, during which period the "mono spot" test and EBV IgM titers are found. IgG titers generally develop during the second month and persist for life.</p><p><b>Dysgammaglobulinemia.</b> In approximately one half of males with XLP1, hypogammaglobulinemia of one or more immunoglobulin subclasses is diagnosed prior to EBV infection or in survivors of EBV infection. Some of these males were previously considered to have common variable immunodeficiency. All lymphoid cell lines (including T cells, B cells, and natural killer cells) can be affected. The natural history of individuals diagnosed with the common variable immunodeficiency <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and subsequently found to have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SH2D1A</i> is not well documented at this time. The prognosis for males with this phenotype is more favorable if they are managed with regular IVIG (see <a href="#x-lpd.Management">Management</a>).</p><p><b>Lymphoproliferative disease (malignant lymphoma).</b> Lymphomas or other lymphoproliferative disease occurs in approximately one third of males with XLP1, some of whom have hypogammaglobulinemia or have survived an initial EBV infection. The lymphomas seen in XLP are typically high-grade B-cell lymphomas, non-Hodgkin type, often extranodal, particularly involving the intestine. Approximately 75% of lymphomas occur in the ileocecal region. Other sites include the central nervous system, liver, and kidney [<a class="bk_pop" href="#x-lpd.REF.gaspar.2002.585">Gaspar et al 2002</a>].</p><p>The lymphomas can be histologically classified as Burkitt lymphoma (53% of all B-cell lymphomas), immunoblastic lymphomas (12% of all lymphomas), small cleaved or mixed-cell lymphomas (12%), and unclassifiable lymphomas (5%) [<a class="bk_pop" href="#x-lpd.REF.harrington.1987.1419">Harrington et al 1987</a>]. Some but not all B-cell lymphomas express the EBV genome, suggesting that the XLP defect alone predisposes to lymphogenesis.</p><p>Lymphomas often develop in childhood and may occur prior to EBV exposure. Remission may follow chemotherapy; however, relapse or development of a second lymphoma or other manifestations of XLP is common [<a class="bk_pop" href="#x-lpd.REF.booth.2011.53">Booth et al 2011</a>].</p><p><b>Common variable immunodeficiency (CVID) and hemophagocytic lymphohistiocytosis (HLH).</b>
<i>SH2D1A</i> pathogenic variants have been described in individuals with phenotypes that overlap with other immunodeficiencies (see <a href="#x-lpd.Differential_Diagnosis">Differential Diagnosis</a>) including the following:</p><ul><li class="half_rhythm"><div>Common variable immunodeficiency (CVID) [<a class="bk_pop" href="#x-lpd.REF.nistala.2001.126">Nistala et al 2001</a>, <a class="bk_pop" href="#x-lpd.REF.soresina.2002.656">Soresina et al 2002</a>, <a class="bk_pop" href="#x-lpd.REF.aghamohammadi.2003.45">Aghamohammadi et al 2003</a>, <a class="bk_pop" href="#x-lpd.REF.eastwood.2004.584">Eastwood et al 2004</a>]</div></li><li class="half_rhythm"><div>Familial hemophagocytic lymphohistiocytosis (FHL) [<a class="bk_pop" href="#x-lpd.REF.arico.2001.1131">Arico et al 2001</a>, <a class="bk_pop" href="#x-lpd.REF.halasa.2003.e136">Halasa et al 2003</a>]</div></li><li class="half_rhythm"><div>Severe EBV-associated illness [<a class="bk_pop" href="#x-lpd.REF.sumazaki.2001.1268">Sumazaki et al 2001</a>]</div></li><li class="half_rhythm"><div>B-cell neoplasms [<a class="bk_pop" href="#x-lpd.REF.sandlund.2013.e85">Sandlund et al 2013</a>]</div></li></ul><p>Males with phenotypes that overlap with other immunodeficiencies and an identified <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should be considered to have XLP and be managed accordingly.</p><p><b>Other.</b> Less frequent manifestations of XLP1 are aplastic anemia, vasculitis, and lymphoid granulomatosis.</p></div><div id="x-lpd.XLP2"><h4>XLP2</h4><p>Males with XIAP deficiency (XLP2) typically present with HLH (often without EBV infection), recurrent episodes of HLH, splenomegaly, and gastrointestinal disease and may be better described as having an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> form of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> HLH rather than XLP. To date, neither lymphoproliferative disease [<a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al 2011</a>] nor common variable immunodeficiency (CVID) has been reported in males with XIAP deficiency [<a class="bk_pop" href="#x-lpd.REF.salzer.2008.147">Salzer et al 2008</a>]. Of note, some males with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>XIAP</i> are asymptomatic and their long-term prognosis is not known.</p><p><a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al [2011]</a> reported mean age at death for males with an <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as 16 years (range 1-52 years). Approximately 43% reached adulthood; none of this group had HCT. In this study, approximately 60% of surviving males were not receiving treatment; 12% received IVIG only; 12% were undergoing treatment for colitis; and 18% were undergoing treatment for HLH. Mortality was related to HLH (30%), complications of HCT (30%), colitis (23%), liver failure (8%), and pneumonia (8%).</p><div id="x-lpd.T.clinical_phenotypes_of_xiap_defi" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Clinical Phenotypes of XIAP Deficiency (XLP2)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1406/table/x-lpd.T.clinical_phenotypes_of_xiap_defi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-lpd.T.clinical_phenotypes_of_xiap_defi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of All Individuals w/XLP2 with This Phenotype&#x000a0;<sup>1</sup></th><th id="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age of Onset</th></tr></thead><tbody><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemophagocytic lymphohistiocytosis (HLH)</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">83%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0-23 yrs&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Recurrent HLH</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">67%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically &#x0003c;1 yr after initial illness&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Splenomegaly</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0-45 yrs&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypogammaglobulinemia</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0-26 yrs&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Colitis &#x000b1; liver disease</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13%</td><td headers="hd_h_x-lpd.T.clinical_phenotypes_of_xiap_defi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4-41 yrs&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="x-lpd.TF.3.1"><p class="no_margin">Combined from series reported to date including <a class="bk_pop" href="#x-lpd.REF.rigaud.2006.110">Rigaud et al [2006]</a>, <a class="bk_pop" href="#x-lpd.REF.marsh.2010.1079">Marsh et al [2010]</a>, <a class="bk_pop" href="#x-lpd.REF.zhao.2010.688">Zhao et al [2010]</a>, and <a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al [2011]</a></p></div></dd><dt>2. </dt><dd><div id="x-lpd.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al [2011]</a></p></div></dd></dl></div></div></div><p><b>Hemophagocytic lymphohistiocytosis (HLH)</b> poses a significant risk for mortality to males with XLP2: 33% of the originally described XLP2 cohort died from HLH between ages six months and 40 years [<a class="bk_pop" href="#x-lpd.REF.rigaud.2006.110">Rigaud et al 2006</a>]. Recurrences of HLH are common, particularly within a year of onset of the initial HLH episode [<a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al 2011</a>].</p><p><b>Colitis,</b> a serious complication of XLP2, has a mortality rate of 60% in symptomatic individuals [<a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al 2011</a>].</p><p><b>Dysgammaglobulinemia.</b> Approximately one third of males with XLP2 have hypogammaglobulinemia of one or more immunoglobulin subclasses, which, if untreated, may result in life-threatening infections. The prognosis for males with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is more favorable if they are managed with regular IVIG (see Management, <a href="#x-lpd.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p><p>Transient hypogammaglobulinemia has been reported in a minority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males.</p><p>In addition, hypergammaglobulinemia has been reported in two males with XIAP deficiency [<a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al 2011</a>].</p></div></div><div id="x-lpd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No strong correlation exists between <i>SH2D1A</i> and <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and XLP1 and XPL2 <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, respectively. Considerable variability in phenotype can be present even within a family [<a class="bk_pop" href="#x-lpd.REF.sumegi.2002.1189">Sumegi et al 2002</a>, <a class="bk_pop" href="#x-lpd.REF.rigaud.2006.110">Rigaud et al 2006</a>, <a class="bk_pop" href="#x-lpd.REF.filipovich.2010.3398">Filipovich et al 2010</a>].</p></div><div id="x-lpd.Nomenclature"><h3>Nomenclature</h3><p>In the past, the following terms were used to describe XLP1:</p><ul><li class="half_rhythm"><div>Epstein-Barr virus infection, <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> fatal</div></li><li class="half_rhythm"><div>EBV susceptibility (EBVS)</div></li><li class="half_rhythm"><div><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> progressive combined variable immunodeficiency 5</div></li><li class="half_rhythm"><div>Purtilo syndrome</div></li><li class="half_rhythm"><div>Duncan disease</div></li></ul></div><div id="x-lpd.Prevalence"><h3>Prevalence</h3><p>The estimated prevalence of XLP is one per one million males. This may be an underestimate given the severity and often rapidly fatal initial presentation, variable expression, clinical overlap with other immunologic disorders, and lack of a functional assay for diagnosis.</p><p>As in many <a class="def" href="/books/n/gene/glossary/def-item/x-linked-recessive/">X-linked recessive</a> disorders, females are rarely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. To the authors' best knowledge, only one affected female (with skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>) has been reported [<a class="bk_pop" href="#x-lpd.REF.holle.2015.1288">Holle et al 2015</a>]. This may be an underestimate of affected females due to the variable clinical presentation of XLP as well as underutilization of testing in the female population.</p><p>XLP has been reported in families of European, African, Asian, and Middle Eastern descent; no evidence exists for a racial or ethnic predilection.</p></div></div><div id="x-lpd.Genetically_Related_Allelic_Disord"><h2 id="_x-lpd_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>SH2D1A</i> or <i>XIAP</i>.</p></div><div id="x-lpd.Differential_Diagnosis"><h2 id="_x-lpd_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> lymphoproliferative disease (XLP) includes the following:</p><ul><li class="half_rhythm"><div><b>Common variable immunodeficiency</b> (CVID; OMIM Phenotypic Series <a href="http://omim.org/phenotypicSeries/PS607594" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607594</a>) is characterized by humoral immune deficiency with onset after age 24 months and usually in young adulthood, resulting in increased susceptibility to infections and diminished responses to protein and polysaccharide vaccines. The most common infections are sinopulmonary. Overall prevalence is approximately one in 30,000 live births and occurs equally in males and females [<a class="bk_pop" href="#x-lpd.REF.stiehm.2005.458">Stiehm &#x00026; Johnston 2005</a>]. The genetic etiology of most CVID is currently unknown. XLP should be considered in males with CVID and hypogammaglobulinemia identified during the first decade of life, particularly in the presence of other symptoms or a positive family history.</div></li><li class="half_rhythm"><div>Hemophagocytic lymphohistiocytosis (HLH) has numerous causes:</div><ul><li class="half_rhythm"><div>Familial hemophagocytic lymphohistiocytosis (FHL), a group of rare <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorders, is characterized by excessive immune activation with uncontrolled T-lymphocyte and macrophage activation. Familial HLH may also be triggered by EBV infection. These disorders are lethal in childhood unless treated with bone marrow transplantation. Four genes (<i>PRF1</i>, <i>UNC13D</i> [<i>MUNC13-4</i>], <i>STXBP2</i>, and <i>STX11</i>), representing approximately 60% of the genetic basis of FHL, have been identified to date.</div></li><li class="half_rhythm"><div>Secondary EBV-associated HLH is commonly diagnosed in Asia [<a class="bk_pop" href="#x-lpd.REF.imashuku.2002.259">Imashuku 2002</a>]; it also accounts for approximately 30% of individuals with HLH identified in North America. Individuals with EBV-associated HLH typically have symptomatic presentation beyond infancy [<a class="bk_pop" href="#x-lpd.REF.filipovich.2001.459">Filipovich 2001</a>] and may achieve prolonged remission with therapy, thus not requiring curative BMT.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#x-lpd.REF.arico.2001.1131">Arico et al [2001]</a> found pathogenic variants in <i>SH2D1A</i> in four of 25 males (16%) who had previously been diagnosed with HLH, suggesting that XLP should be considered in males presenting with HLH who have no family history of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females. Similarly, <a class="bk_pop" href="#x-lpd.REF.marsh.2010.1079">Marsh et al [2010]</a> published a series of young males who presented with HLH and an <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, prompting the conclusion that XIAP deficiency may be most appropriately classified as an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> form of hemophagocytic lymphohistiocytosis rather than an X-linked lymphoproliferative disease.</div></li></ul></li><li class="half_rhythm"><div><b>Severe EBV-associated illness.</b> Approximately one in 1,000 persons infected with EBV develops severe EBV-associated illness. XLP1 and XLP2 should be considered in males with severe EBV-associated illness who fail to respond to conventional therapies, develop secondary symptoms, or have a family history of severe EBV-associated illness. Aplastic anemia is an uncommon but serious complication of severe EBV-associated illness.</div></li><li class="half_rhythm"><div><b>Recurrent lymphoma.</b> XLP1 should be suspected in boys treated for lymphoma with standard chemotherapy who develop a second distinct lymphoma (not relapse) after achieving initial remission [<a class="bk_pop" href="#x-lpd.REF.sandlund.2013.e85">Sandlund et al 2013</a>]. To date, lymphoma as a complication of XLP2 has not been reported.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/chediak-higashi/"><b>Chediak-Higashi syndrome</b></a> is characterized by partial oculocutaneous albinism, a mild bleeding tendency, and severe immunodeficiency. Mutation of <i>LYST</i>, encoding a protein involved in intracellular vesicle formation, is causative, resulting in failure to fuse lysosomes properly with phagosomes. Chediak-Higashi syndrome can be differentiated from XLP based on the presence of huge secretory lysosomes in the neutrophils and lymphocytes and giant melanosomes on skin biopsy. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>Griscelli syndrome type 2</b> (GS2; OMIM <a href="http://omim.org/entry/607624" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607624</a>) is a disorder of cytotoxic T lymphocytes caused by mutation of <i>RAB27A</i>, encoding a small GTPase, which controls the movement of vesicles within cells [<a class="bk_pop" href="#x-lpd.REF.m_nasch_.2002.1237">M&#x000e9;nasch&#x000e9; et al 2002</a>]. GS2 is usually associated with neurologic abnormalities in addition to partial albinism with fair skin and silvery-gray hair. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>ITK deficiency</b> (lymphoproliferative syndrome 1; OMIM <a href="http://omim.org/entry/613011" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613011</a>). Pathogenic variants in <i>ITK</i> have been reported in association with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> form of lymphoproliferative disease [<a class="bk_pop" href="#x-lpd.REF.huck.2009.1350">Huck et al 2009</a>, <a class="bk_pop" href="#x-lpd.REF.stepensky.2011.472">Stepensky et al 2011</a>]. Presentation has been quite variable in the few individuals reported to date and has included fatal hemophagocytic lymphohistiocytosis, hypogammaglobulinemia, and autoimmune-mediated renal disease, often following EBV infection. In contrast to XLP1, four out of five individuals with ITK deficiency developed Hodgkin disease, as opposed to Burkitt lymphoma.</div></li><li class="half_rhythm"><div><b>CD27 deficiency</b> (lymphoproliferative syndrome 2; OMIM <a href="http://omim.org/entry/615122" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615122</a>). Pathogenic variants in <i>TNFRSF7</i> have been reported in association with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> form of lymphoproliferative disease [<a class="bk_pop" href="#x-lpd.REF.van_montfrans.2012.787">van Montfrans et al 2012</a>, <a class="bk_pop" href="#x-lpd.REF.salzer.2013.473">Salzer et al 2013</a>]. This condition is characterized by EBV viremia, hypogammaglobulinemia, and T-cell dysfunction.</div></li></ul></div><div id="x-lpd.Management"><h2 id="_x-lpd_Management_">Management</h2><div id="x-lpd.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> lymphoproliferative disease (XLP), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Physical examination to evaluate for rashes, lymphadenopathy, hepatosplenomegaly, and neurologic dysfunction</div></li><li class="half_rhythm"><div>Evaluation of blood and bone marrow compartments (CBC and bone marrow biopsy)</div></li><li class="half_rhythm"><div>Determination of the extent of liver involvement by measuring serum concentration of transaminases, bilirubin, triglycerides, sodium, and lactate dehydrogenase</div></li><li class="half_rhythm"><div>Identification of potential infectious cofactors (especially viral infection or reactivation) that would require specific treatment</div></li><li class="half_rhythm"><div>Testing to assess immune function including lymphocyte subset analysis (T cell, B cell, NK cell) and serum concentrations of IgG, IgM, and IgA</div></li><li class="half_rhythm"><div>Establishing the presence or extent of CNS involvement by evaluating the CSF and performing neuroimaging and neuropsychological assessment</div></li><li class="half_rhythm"><div>Evaluation of inflammatory factors including serum concentrations of ferritin, sIL2R&#x003b1;, and other cytokines</div></li><li class="half_rhythm"><div>Evaluation and monitoring of PT, PTT, and fibrinogen</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="x-lpd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>No formal management guidelines exist; the following are general considerations.</p><p>Individuals with XLP who develop fulminant EBV infection / HLH often improve with early treatment (e.g., based on HLH-1994 protocol) similar to that used in other life-threatening genetic hemophagocytic disorders including <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemophagocytic lymphohistiocytosis (FHL) [<a class="bk_pop" href="#x-lpd.REF.henter.1997.342">Henter et al 1997</a>, <a class="bk_pop" href="#x-lpd.REF.jordan.2011.4041">Jordan et al 2011</a>], typically consisting of etoposide and steroids. Rituximab (anti-CD20 antibody) [<a class="bk_pop" href="#x-lpd.REF.milone.2005.994">Milone et al 2005</a>, <a class="bk_pop" href="#x-lpd.REF.lee.2006.210">Lee et al 2006</a>] as well as IVIG may also be considered.</p><p>Allogeneic HCT is the only curative therapy and should be strongly considered in individuals with confirmed XLP1 as early in life as is feasible [<a class="bk_pop" href="#x-lpd.REF.lankester.2005.99">Lankester et al 2005</a>]. Successful outcomes have been reported with the use of matched sib donors and marrow or umbilical cord blood from unrelated donors [<a class="bk_pop" href="#x-lpd.REF.gross.1996.741">Gross et al 1996</a>, <a class="bk_pop" href="#x-lpd.REF.filipovich.2001.459">Filipovich 2001</a>, <a class="bk_pop" href="#x-lpd.REF.lankester.2005.99">Lankester et al 2005</a>]. Overall survival appears to be approximately 80%, regardless of conditioning regimen used. However, survival of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who received a transplant was increased if they were transplanted prior to an episode of HLH [<a class="bk_pop" href="#x-lpd.REF.booth.2011.53">Booth et al 2011</a>].</p><p>The outcomes of allogeneic HCT for males with XLP2 are less certain at this time. Early evidence suggests that reduced-intensity conditioning regimens should be considered due to very poor early experience with myeloablative preparative regimens [<a class="bk_pop" href="#x-lpd.REF.marsh.2013.877">Marsh et al 2013</a>].</p><p>Hypogammaglobulinemia is treated with IVIG.</p><p>Lymphoma associated with XLP1 is treated with the standard chemotherapy appropriate to the tumor diagnosis. Once lymphoma remission is achieved, the individual should quickly proceed to allogeneic HCT.</p><p>Colitis associated with XLP2 is treated symptomatically and with immunosuppression similar to that used for inflammatory bowel disease of other etiologies.</p></div><div id="x-lpd.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><p>It is recommended that boys with known or suspected XLP and hypogammaglobulinemia receive regular intravenous (IV) IgG replacement therapy every three to four weeks until definitive treatment can be provided.</p><p>HCT is the only curative therapy and should be considered in children with confirmed XLP as early in life as possible.</p></div><div id="x-lpd.Surveillance"><h3>Surveillance</h3><p>No formal surveillance guidelines exist; the following are general considerations:</p><ul><li class="half_rhythm"><div>Blood should be monitored by EBV-<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> for evidence of EBV infection if symptoms of infection or HLH develop.</div></li><li class="half_rhythm"><div>Blood counts, hepatic profiles, coagulation studies, and inflammatory markers (ferritin, soluble IL2R) should be monitored as needed based on clinical status for early evidence of HLH.</div></li><li class="half_rhythm"><div>IgG levels should also be monitored as needed based on clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li></ul></div><div id="x-lpd.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Individuals with XLP who come into contact with EBV are at risk until curative treatment with allogeneic HCT has been performed. Individuals are also at risk of developing HLH or inflammatory problems with other infections.</p></div><div id="x-lpd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Once the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk sibs and other maternal male relatives is appropriate for medical management and for consideration of presymptomatic bone marrow transplantation.</p><p>See <a href="#x-lpd.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes</p></div><div id="x-lpd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="x-lpd.Genetic_Counseling"><h2 id="_x-lpd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="x-lpd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> lymphoproliferative disease (XLP) is inherited in an X-linked manner.</p></div><div id="x-lpd.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have XLP, nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div class="half_rhythm">In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Female carriers of XLP are typically asymptomatic with no immunologic or biochemical markers of the disorder (in rare cases, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females may be symptomatic due to skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>).</div><div class="half_rhythm">Note: If a woman has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> son and no other affected relatives and if the <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Germline mosaicism has been reported [<a class="bk_pop" href="#x-lpd.REF.schuster.1993.1303">Schuster et al 1993</a>]; the frequency of germline mosaicism in XLP is currently unknown.</div></li><li class="half_rhythm"><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a carrier.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs depends on the genetic status of the mother.</div></li><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting the pathogenic variant in each pregnancy is 50%. Male sibs who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; female sibs who inherit the pathogenic variant will be carriers. Female carriers of XLP are typically asymptomatic with no immunologic or biochemical markers of the disorder (in rare cases, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females may be symptomatic due to skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>).</div></li><li class="half_rhythm"><div>Germline <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> has been demonstrated [<a class="bk_pop" href="#x-lpd.REF.schuster.1993.1303">Schuster et al 1993</a>]. Thus, even if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified in DNA extracted from the mother's leukocytes, her offspring are still at increased risk.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>It is likely that in the near future some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males will live to reproduce following bone marrow transplantation given that reduced-intensity conditioning regimens &#x02013; which may not render them infertile &#x02013; are being more frequently used. However, the likelihood of this is unknown at the present time.</div></li><li class="half_rhythm"><div>Affected males would transmit the <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</div><ul><li class="half_rhythm"><div>All of their daughters, who would be heterozygotes and typically unaffected;</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal relatives and their offspring may be at risk of being carriers (if female) or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with XLP (if male).</div></li><li class="half_rhythm"><div>The exact risk to the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal relatives depends on the family relationships.</div></li></ul></div><div id="x-lpd.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Identification of female heterozygotes requires either (a) prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>. Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (carriers) for an <i>SH2D1A</i> or <i>XIAP</i> pathogenic variant are asymptomatic and have no immunologic or biochemical markers of the disorder.</p><p>Note: <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> studies are not suitable for determining <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status [<a class="bk_pop" href="#x-lpd.REF.harris.1992.608">Harris et al 1992</a>].</p></div><div id="x-lpd.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#x-lpd.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="x-lpd.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SH2D1A</i> or <i>XIAP</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for XLP are possible.</p><p>In pregnancies where the fetus is found to be unaffected, prenatal identification of an HLA-matched potential stem cell donor for an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sib may be considered.</p></div></div><div id="x-lpd.Resources"><h2 id="_x-lpd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Histiocytosis Association</b></div><div> NJ </div><div><b>Phone:</b> 856-589-6606</div><div><b>Fax:</b> 856-589-6614</div><div><b>Email:</b> info@histio.org</div><div><a href="https://www.histio.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.histio.org</a></div></li><li class="half_rhythm"><div><b>Jeffrey Modell Foundation/National Primary Immunodeficiency Resource Center</b></div><div>747 Third Avenue</div><div>New York NY 10017</div><div><b>Phone:</b> 866-463-6474 (toll-free); 212-819-0200</div><div><b>Fax:</b> 212-764-4180</div><div><b>Email:</b> info@jmfworld.org</div><div><a href="http://www.info4pi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.info4pi.org</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li></ul></div><div id="x-lpd.Molecular_Genetics"><h2 id="_x-lpd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="x-lpd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Lymphoproliferative Disease, X-Linked: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1406/table/x-lpd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-lpd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_x-lpd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_x-lpd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_x-lpd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_x-lpd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_x-lpd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_x-lpd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_x-lpd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4068" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SH2D1A</i></a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4068" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq25</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O60880" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SH2 domain-containing protein 1A</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=SH2D1A" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (SH2D1A)</a><br /><a href="http://structure.bmc.lu.se/idbase/SH2D1Abase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SH2D1Abase: Mutation registry for X-linked lymphoproliferative syndrome (XLP)</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SH2D1A" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SH2D1A</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SH2D1A[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SH2D1A</a></td></tr><tr><td headers="hd_b_x-lpd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/331" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>XIAP</i></a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=331" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq25</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P98170" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">E3 ubiquitin-protein ligase XIAP</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/XIAP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XIAP @ LOVD</a><br /><a href="https://research.cchmc.org/LOVD2/home.php?select_db=XIAP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (XIAP)</a><br /><a href="http://structure.bmc.lu.se/idbase/BIRC4base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mutation registry for X-linked lymphoproliferative syndrome (XIAP)</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=XIAP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XIAP</a></td><td headers="hd_b_x-lpd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=XIAP[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XIAP</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="x-lpd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="x-lpd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Lymphoproliferative Disease, X-Linked (<a href="/omim/300079,300490,300635,308240" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1406/table/x-lpd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-lpd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300079" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300079</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INHIBITOR OF APOPTOSIS, X-LINKED; XIAP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300490" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300490</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SH2 DOMAIN PROTEIN 1A; SH2D1A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300635" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300635</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2; XLP2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/308240" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">308240</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1</td></tr></tbody></table></div></div><p><b><i>SH2D1A</i></b></p><p><b>Gene structure.</b>
<i>SH2D1A</i> has four exons (<a href="/nuccore/NM_002351.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002351.4</a>) that span more than 25 kb. See <a href="/books/NBK1406/#x-lpd.molgen.TA">Table A</a> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> More than 113 <i>SH2D1A</i> pathogenic variants that result in the XLP-associated <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have been identified. Pathogenic variants have been found in all four exons and include deletions and insertions that lead to absence of a functional protein, pathogenic variants that interfere with transcription and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants predicted to result in protein truncation, and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that affect protein function [<a class="bk_pop" href="#x-lpd.REF.sumegi.2002.1189">Sumegi et al 2002</a>]. One half of these pathogenic variants are single-nucleotide substitutions, one quarter are splicing defects or frameshift variants, and one quarter are large (i.e., [multi]<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>) deletions. These pathogenic variants result in improper processing of the <i>SH2D1A</i> message and lead to truncated or unstable protein [<a class="bk_pop" href="#x-lpd.REF.morra.2001.36809">Morra et al 2001</a>, <a class="bk_pop" href="#x-lpd.REF.li.2003.14885">Li et al 2003</a>, <a class="bk_pop" href="#x-lpd.REF.stenson.2003.577">Stenson et al 2003</a>, <a class="bk_pop" href="#x-lpd.REF.erd_s.2005.506">Erd&#x000f5;s et al 2005</a>, <a class="bk_pop" href="#x-lpd.REF.friedlander.2008.398">Friedlander et al 2008</a>, <a class="bk_pop" href="#x-lpd.REF.marsh.2009.116">Marsh et al 2009</a>, <a class="bk_pop" href="#x-lpd.REF.snow.2009.2976">Snow et al 2009</a>, <a class="bk_pop" href="#x-lpd.REF.marsh.2010.1079">Marsh et al 2010</a>, <a class="bk_pop" href="#x-lpd.REF.gifford.2014.263">Gifford et al 2014</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>SH2D1A</i> codes for SH2 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> protein 1A (signaling lymphocyte activation molecular [SLAM]-associated protein, or SAP), a small 125-amino acid protein (<a href="/protein/NP_002342.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002342.1</a>) involved in the intracellular signaling of the SLAM family of receptors [<a class="bk_pop" href="#x-lpd.REF.veillette.2006.56">Veillette 2006</a>, <a class="bk_pop" href="#x-lpd.REF.ma.2007.337">Ma et al 2007</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>SH2D1A</i> lead to changes in the amino acid sequence and truncation or absence of SAP, which disrupts binding to SLAM family receptors and resultant signal transduction pathways [<a class="bk_pop" href="#x-lpd.REF.sayos.1998.462">Sayos et al 1998</a>, <a class="bk_pop" href="#x-lpd.REF.morra.2001.36809">Morra et al 2001</a>]. Loss of functional SAP causes intrinsic defects in lymphocyte function including lymphocyte cytotoxicity, cytokine production by T cells, T cell-dependent humoral immune responses, and development of NKT cells [<a class="bk_pop" href="#x-lpd.REF.veillette.2006.56">Veillette 2006</a>, <a class="bk_pop" href="#x-lpd.REF.ma.2007.337">Ma et al 2007</a>]. It is likely that additional functions that could be disturbed by certain pathogenic variants of <i>SH2D1A</i> will be defined in the future.</p><p><b><i>XIAP</i> (<i>BIRC4</i>)</b></p><p><b>Gene structure.</b>
<i>XIAP</i> has seven exons (<a href="/nuccore/NM_001167.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001167.3</a>) that encode a 497-amino acid protein. See <a href="/books/NBK1406/#x-lpd.molgen.TA">Table A</a> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> Three pathogenic variants in <i>XIAP</i> were described in the original cohort of individuals with XLP2. Two families were found to have pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants resulting in early stop codons within <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1, and the third family was described with a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> spanning exon 2 [<a class="bk_pop" href="#x-lpd.REF.rigaud.2006.110">Rigaud et al 2006</a>]. To date more than 70 pathogenic variants have been identified in <i>XIAP</i>, including nonsense and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants and deletions [<a class="bk_pop" href="#x-lpd.REF.marsh.2010.1079">Marsh et al 2010</a>, <a class="bk_pop" href="#x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid et al 2011</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>XIAP</i> encodes E3 ubiquitin-protein ligase XIAP. As the name implies, XIAP is known to inhibit apoptosis through interaction with caspase-3, -7, and -9. XIAP also has a C-terminal ring finger <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> with E3 ubiquitin ligase activity. XIAP is involved in signaling pathways involving nuclear factor-kappa beta, JNK, and TGF-&#x003b2;, and is also involved in intracellular copper homeostasis [<a class="bk_pop" href="#x-lpd.REF.mufti.2007.168">Mufti et al 2007</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The majority of <i>XIAP</i> pathogenic variants lead to an absence of protein expression [<a class="bk_pop" href="#x-lpd.REF.rigaud.2006.110">Rigaud et al 2006</a>, <a class="bk_pop" href="#x-lpd.REF.marsh.2009.116">Marsh et al 2009</a>]. How this results in the XLP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> remains to be definitively explained, but an increased <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of XIAP-deficient lymphocytes to apoptosis and decreased populations of NKT cells have been postulated to contribute to disease pathogenesis [<a class="bk_pop" href="#x-lpd.REF.rigaud.2006.110">Rigaud et al 2006</a>, <a class="bk_pop" href="#x-lpd.REF.latour.2007.510">Latour 2007</a>, <a class="bk_pop" href="#x-lpd.REF.marsh.2009.116">Marsh et al 2009</a>].</p></div><div id="x-lpd.References"><h2 id="_x-lpd_References_">References</h2><div id="x-lpd.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF1">American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. ASHG statement. Professional disclosure of familial genetic information. Available <a href="http://www.sciencedirect.com/science/article/pii/S0002929707635101" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>.1998. Accessed 9-27-19. [<a href="/pmc/articles/PMC1376910/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376910</span></a>] [<a href="/pubmed/9537923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9537923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF2">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 9-27-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li></ul></div><div id="x-lpd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.aghamohammadi.2003.45">Aghamohammadi A, Kanegane H, Moein M, Farhoudi A, Pourpak Z, Movahedi M, Gharagozlou M, Zargar AA, Miyawaki T. Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency. <span><span class="ref-journal">Int J Hematol. </span>2003;<span class="ref-vol">78</span>:45–7.</span> [<a href="/pubmed/12894850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12894850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.arico.2001.1131">Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, Haber DA, Nichols KE. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>:1131–3.</span> [<a href="/pubmed/11159547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11159547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.booth.2011.53">Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, Heath PT, Steward CG, Smith O, O'Meara A, Kerrigan H, Mahlaoui N, Cavazzana-Calvo M, Fischer A, Moshous D, Blanche S, Pachlopnick-Schmid J, Latour S, de Saint-Basile G, Albert M, Notheis G, Rieber N, Strahm B, Ritterbusch H, Lankester A, Hartwig NG, Meyts I, Plebani A, Soresina A, Finocchi A, Pignata C, Cirillo E, Bonanomi S, Peters C, Kalwak K, Pasic S, Sedlacek P, Jazbec J, Kanegane H, Nichols KE, Hanson IC, Kapoor N, Haddad E, Cowan M, Choo S, Smart J, Arkwright PD, Gaspar HB. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:53–62.</span> [<a href="/pmc/articles/PMC3374620/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3374620</span></a>] [<a href="/pubmed/20926771" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20926771</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.eastwood.2004.584">Eastwood D, Gilmour KC, Nistala K, Meaney C, Chapel H, Sherrell Z, Webster AD, Davies EG, Jones A, Gaspar HB. Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency. <span><span class="ref-journal">Clin Exp Immunol. </span>2004;<span class="ref-vol">137</span>:584–8.</span> [<a href="/pmc/articles/PMC1809139/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1809139</span></a>] [<a href="/pubmed/15320910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15320910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.erd_s.2005.506">Erd&#x000f5;s M, Uzv&#x000f6;lgyi E, Nemes Z, T&#x000f6;r&#x000f6;k O, R&#x000e1;k&#x000f3;czi E, Went-S&#x000fc;megi N, S&#x000fc;megi J, Mar&#x000f3;di L. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:506.</span> [<a href="/pubmed/15841490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15841490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.filipovich.2001.459">Filipovich AH. Unrelated cord blood transplantation for correction of genetic immunodeficiencies. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:459–61.</span> [<a href="/pubmed/11295705" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11295705</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.filipovich.2010.3398">Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:3398–408.</span> [<a href="/pmc/articles/PMC2981470/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2981470</span></a>] [<a href="/pubmed/20660790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20660790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.friedlander.2008.398">Friedlander SL, Dooms KT, Seroogy CM, Voss CY, Agger WA, Zhang K, Bleesing J, Filipovich AH. Adolescent presentation of X-linked lymphoproliferative disease. <span><span class="ref-journal">Ann Allergy Asthma Immunol. </span>2008;<span class="ref-vol">100</span>:398–400.</span> [<a href="/pubmed/18450131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18450131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.gaspar.2002.585">Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">119</span>:585–95.</span> [<a href="/pubmed/12437631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12437631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.gifford.2014.263">Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA. Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP/BIRC4 mutations. <span><span class="ref-journal">Cytometry B Clin Cytom. </span>2014;<span class="ref-vol">86</span>:263–71.</span> [<a href="/pubmed/24616127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24616127</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.gross.1996.741">Gross TG, Filipovich AH, Conley ME, Pracher E, Schmiegelow K, Verdirame JD, Vowels M, Williams LL, Seemayer TA. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. <span><span class="ref-journal">Bone Marrow Transplant. </span>1996;<span class="ref-vol">17</span>:741–4.</span> [<a href="/pubmed/8733691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8733691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.halasa.2003.e136">Halasa NB, Whitlock JA, McCurley TL, Smith JA, Zhu Q, Ochs H, Dermody TS, Crowe JE Jr. Fatal hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection in a patient with a novel mutation in the signaling lymphocytic activation molecule-associated protein. <span><span class="ref-journal">Clin Infect Dis. </span>2003;<span class="ref-vol">37</span>:e136–41.</span> [<a href="/pubmed/14583885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14583885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.harrington.1987.1419">Harrington DS, Weisenburger DD, Purtilo DT. Malignant lymphoma in the X-linked lymphoproliferative syndrome. <span><span class="ref-journal">Cancer. </span>1987;<span class="ref-vol">59</span>:1419–29.</span> [<a href="/pubmed/3815312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3815312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.harris.1992.608">Harris A, Collins J, Vetrie D, Cole C, Bobrow M. X inactivation as a mechanism of selection against lethal alleles: further investigation of incontinentia pigmenti and X linked lymphoproliferative disease. <span><span class="ref-journal">J Med Genet. </span>1992;<span class="ref-vol">29</span>:608–14.</span> [<a href="/pmc/articles/PMC1016090/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1016090</span></a>] [<a href="/pubmed/1404291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1404291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.holle.2015.1288">Holle JR, Marsh R, Holdcroft AM, Davies SM, Wang L, Zhang K, Jordan MB. Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous XIAP mutation and skewed X chromosome inactivation. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2015;<span class="ref-vol">62</span>:1288–90.</span> [<a href="/pubmed/25801017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25801017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.henter.1997.342">Henter JI, Aric&#x000f2; M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. <span><span class="ref-journal">Med Pediatr Oncol. </span>1997;<span class="ref-vol">28</span>:342–7.</span> [<a href="/pubmed/9121398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9121398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.huck.2009.1350">Huck K, Feyen O, Niehues T, R&#x000fc;schendorf F, H&#x000fc;bner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A, Jumaa H, Borkhardt A. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:1350–8.</span> [<a href="/pmc/articles/PMC2673872/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2673872</span></a>] [<a href="/pubmed/19425169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19425169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.imashuku.2002.259">Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Crit Rev Oncol Hematol. </span>2002;<span class="ref-vol">44</span>:259–72.</span> [<a href="/pubmed/12467966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12467966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.jordan.2011.4041">Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:4041–52.</span> [<a href="/pmc/articles/PMC3204727/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3204727</span></a>] [<a href="/pubmed/21828139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21828139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.lankester.2005.99">Lankester AC, Visser LF, Hartwig NG, Bredius RG, Gaspar HB, van der Burg M, van Tol MJ, Gross TG, Egeler RM. Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. <span><span class="ref-journal">Bone Marrow Transplant. </span>2005;<span class="ref-vol">36</span>:99–105.</span> [<a href="/pubmed/15908972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15908972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.latour.2007.510">Latour S. Natural killer T cells and X-linked lymphoproliferative syndrome. <span><span class="ref-journal">Curr Opin Allergy Clin Immunol. </span>2007;<span class="ref-vol">7</span>:510–4.</span> [<a href="/pubmed/17989527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17989527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.lee.2006.210">Lee TL, Law HKW, Chan GCF, Ha SY, Ho MHK, Chan KW, Lau YL. Successful treatment of X-linked lymphoproliferative disease (XLP) with anti-CD20 monoclonal antibody (Rituximab) followed by mismatched unrelated cord blood transplantation. <span><span class="ref-journal">HK J Paediatr. </span>2006;<span class="ref-vol">11</span>:210–4.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.li.2003.14885">Li C, Iosef C, Jia CY, Gkourasas T, Han VK, Shun-Cheng Li S. Disease-causing SAP mutants are defective in ligand binding and protein folding. <span><span class="ref-journal">Biochemistry. </span>2003;<span class="ref-vol">42</span>:14885–92.</span> [<a href="/pubmed/14674764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14674764</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.ma.2007.337">Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. <span><span class="ref-journal">Annu Rev Immunol. </span>2007;<span class="ref-vol">25</span>:337–79.</span> [<a href="/pubmed/17201683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17201683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.marsh.2010.1079">Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:1079–82.</span> [<a href="/pmc/articles/PMC2938130/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2938130</span></a>] [<a href="/pubmed/20489057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20489057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.marsh.2013.877">Marsh RA, Rao K, Satwani P, Lehmberg K, M&#x000fc;ller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">121</span>:877–83.</span> [<a href="/pmc/articles/PMC5162550/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5162550</span></a>] [<a href="/pubmed/23131490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23131490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.marsh.2009.116">Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. <span><span class="ref-journal">Clin Immunol. </span>2009;<span class="ref-vol">132</span>:116–23.</span> [<a href="/pmc/articles/PMC2729708/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2729708</span></a>] [<a href="/pubmed/19398375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19398375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.m_nasch_.2002.1237">M&#x000e9;nasch&#x000e9; G, Fischer A, de Saint Basile G. Griscelli syndrome types 1 and 2. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:1237–8.</span> [<a href="/pmc/articles/PMC385107/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC385107</span></a>] [<a href="/pubmed/12452176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12452176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.milone.2005.994">Milone MC, Tsai DE, Hodinka RL, Silverman LB, Malbran A, Wasik MA, Nichols KE. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:994–6.</span> [<a href="/pubmed/15494422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15494422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.morra.2001.36809">Morra M, Simarro-Grande M, Martin M, Chen AS, Lanyi A, Silander O, Calpe S, Davis J, Pawson T, Eck MJ, Sumegi J, Engel P, Li SC, Terhorst C. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:36809–16.</span> [<a href="/pubmed/11477068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11477068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.mufti.2007.168">Mufti AR, Burstein E, Duckett CS. XIAP: cell death regulation meets copper homeostasis. <span><span class="ref-journal">Arch Biochem Biophys. </span>2007;<span class="ref-vol">463</span>:168–74.</span> [<a href="/pmc/articles/PMC1986780/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1986780</span></a>] [<a href="/pubmed/17382285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17382285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.nistala.2001.126">Nistala K, Gilmour KC, Cranston T, Davies EG, Goldblatt D, Gaspar HB, Jones AM. X-linked lymphoproliferative disease: three atypical cases. <span><span class="ref-journal">Clin Exp Immunol. </span>2001;<span class="ref-vol">126</span>:126–30.</span> [<a href="/pmc/articles/PMC1906162/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1906162</span></a>] [<a href="/pubmed/11678908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11678908</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.pachlopnik_schmid.2011.1522">Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, Kanegane H, Lopez-Granados E, Mejstrikova E, Pellier I, Galicier L, Galambrun C, Barlogis V, Bordigoni P, Fourmaintraux A, Hamidou M, Dabadie A, Le Deist F, Haerynck F, Ouach&#x000e9;e-Chardin M, Rohrlich P, Stephan JL, Lenoir C, Rigaud S, Lambert N, Milili M, Schiff C, Chapel H, Picard C, de Saint Basile G, Blanche S, Fischer A, Latour S. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:1522–9.</span> [<a href="/pubmed/21119115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21119115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.rigaud.2006.110">Rigaud S, Fondan&#x000e8;che MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Saint Basile G, Latour S. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">444</span>:110–4.</span> [<a href="/pubmed/17080092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17080092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.salzer.2013.473">Salzer E, Daschkey S, Choo S, Gombert M, Santos-Valente E, Ginzel S, Schwendinger M, Haas OA, Fritsch G, Pickl WF, F&#x000f6;rster-Waldl E, Borkhardt A, Boztug K, Bienemann K, Seidel MG. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. <span><span class="ref-journal">Haematologica. </span>2013;<span class="ref-vol">98</span>:473–8.</span> [<a href="/pmc/articles/PMC3659923/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3659923</span></a>] [<a href="/pubmed/22801960" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22801960</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.salzer.2008.147">Salzer U, Hagena T, Webster DB, Grimbacher B. Sequence analysis of BIRC4/XIAP in male patients with common variable immunodeficiency. <span><span class="ref-journal">Int Arch Allergy Immunol. </span>2008;<span class="ref-vol">147</span>:147–51.</span> [<a href="/pubmed/18520160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18520160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.sandlund.2013.e85">Sandlund JT, Shurtleff SA, Onciu M, Horwitz E, Leung W, Howard V, Rencher R, Conley ME. Frequent mutations in SH2D1A (XLP) in males presenting with high-grade mature B-cell neoplasms. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2013;<span class="ref-vol">60</span>:E85–87.</span> [<a href="/pmc/articles/PMC4758190/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4758190</span></a>] [<a href="/pubmed/23589280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23589280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.sayos.1998.462">Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, van Schaik S, Notarangelo L, Geha R, Roncarolo MG, Oettgen H, De Vries JE, Aversa G, Terhorst C. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. <span><span class="ref-journal">Nature. </span>1998;<span class="ref-vol">395</span>:462–9.</span> [<a href="/pubmed/9774102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9774102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.schuster.1993.1303">Schuster V, Kress W, Friedrich W, Grimm T, Kreth HW. X-linked lymphoproliferative disease. Detection of a paternally inherited mutation in a German family using haplotype analysis. <span><span class="ref-journal">Am J Dis Child. </span>1993;<span class="ref-vol">147</span>:1303–5.</span> [<a href="/pubmed/8249949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8249949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.snow.2009.2976">Snow AL, Marsh RA, Krummey SM, Roehrs P, Young LR, Zhang K, van Hoff J, Dhar D, Nichols KE, Filipovich AH, Su HC, Bleesing JJ, Lenardo MJ. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:2976–89.</span> [<a href="/pmc/articles/PMC2752081/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2752081</span></a>] [<a href="/pubmed/19759517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19759517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.soresina.2002.656">Soresina A, Lougaris V, Giliani S, Cardinale F, Armenio L, Cattalini M, Notarangelo LD, Plebani A. Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency. <span><span class="ref-journal">Eur J Pediatr. </span>2002;<span class="ref-vol">161</span>:656–9.</span> [<a href="/pubmed/12447665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12447665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.stenson.2003.577">Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. Human Gene Mutation Database (HGMD): 2003 update. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">21</span>:577–81.</span> [<a href="/pubmed/12754702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12754702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.stepensky.2011.472">Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, Linka RM, Shaag A, Elpeleg O, Borkhardt A, Resnick IB. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. <span><span class="ref-journal">Haematologica. </span>2011;<span class="ref-vol">96</span>:472–6.</span> [<a href="/pmc/articles/PMC3046282/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3046282</span></a>] [<a href="/pubmed/21109689" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21109689</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.sumazaki.2001.1268">Sumazaki R, Kanegane H, Osaki M, Fukushima T, Tsuchida M, Matsukura H, Shinozaki K, Kimura H, Matsui A, Miyawaki T. SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">98</span>:1268–70.</span> [<a href="/pubmed/11493483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11493483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.sumegi.2000.3118">Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, Klein G, Seri M, Wakiguchi H, Purtilo DT, Gross TG. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">96</span>:3118–25.</span> [<a href="/pubmed/11049992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11049992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.sumegi.2002.1189">Sumegi J, Seemayer TA, Huang D, Davis JR, Morra M, Gross TG, Yin L, Romco G, Klein E, Terhorst C, Lanyi A. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. <span><span class="ref-journal">Leuk Lymphoma. </span>2002;<span class="ref-vol">43</span>:1189–201.</span> [<a href="/pubmed/12152986" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12152986</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.stiehm.2005.458">Stiehm ER, Johnston RB Jr. A history of pediatric immunology. <span><span class="ref-journal">Pediatr Res. </span>2005;<span class="ref-vol">57</span>:458–67.</span> [<a href="/pubmed/15611343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15611343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.van_montfrans.2012.787">van Montfrans JM, Hoepelman AI, Otto S, van Gijn M, van de Corput L, de Weger RA, Monaco-Shawver L, Banerjee PP, Sanders EA, Jol-van der Zijde CM, Betts MR, Orange JS, Bloem AC, Tesselaar K. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2012;<span class="ref-vol">129</span>:787–93.e6.</span> [<a href="/pmc/articles/PMC3294016/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3294016</span></a>] [<a href="/pubmed/22197273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22197273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.veillette.2006.56">Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. <span><span class="ref-journal">Nat Rev Immunol. </span>2006;<span class="ref-vol">6</span>:56–66.</span> [<a href="/pubmed/16493427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16493427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-lpd.REF.zhao.2010.688">Zhao M, Kanegane H, Ouchi K, Imamura T, Latour S, Miyawaki T. A novel XIAP mutation in a Japanese boy with recurrent pancytopenia and splenomegaly. <span><span class="ref-journal">Haematologica. </span>2010;<span class="ref-vol">95</span>:688–9.</span> [<a href="/pmc/articles/PMC2857205/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2857205</span></a>] [<a href="/pubmed/20015872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20015872</span></a>]</div></li></ul></div></div><div id="x-lpd.Chapter_Notes"><h2 id="_x-lpd_Chapter_Notes_">Chapter Notes</h2><div id="x-lpd.Author_History"><h3>Author History</h3><p>Alexandra Filipovich, MD; Cincinnati Children's Hospital Medical Center (2004-2016)<br />Judith Johnson, MS; Cincinnati Children's Hospital Medical Center (2004-2016)<br />Rebecca Marsh, MD (2009-present)<br />Janos Sumegi, MD, PhD; Cincinnati Children's Hospital Medical Center (2004-2011)<br />Emily Wakefield, MS (2016-present)<br />Kejian Zhang, MD, MBA (2004-present)</p></div><div id="x-lpd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>30 June 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 September 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 November 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 June 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 August 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 February 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>10 August 2003 (js) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1406</span><span class="label">PMID: <a href="/pubmed/20301580" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301580</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/lds/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hnpcc/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1406&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1406/?report=reader">PubReader</a></li><li><a href="/books/NBK1406/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1406" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1406" style="display:none" title="Cite this Page"><div class="bk_tt">Zhang K, Wakefield E, Marsh R. Lymphoproliferative Disease, X-Linked. 2004 Feb 27 [Updated 2016 Jun 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1406/pdf/Bookshelf_NBK1406.pdf">PDF version of this page</a> (481K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#x-lpd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#x-lpd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#x-lpd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#x-lpd.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#x-lpd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#x-lpd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#x-lpd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#x-lpd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#x-lpd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#x-lpd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#x-lpd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4068[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SH2D1A</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=331[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">XIAP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1488798" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1488798" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1488798" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1488798" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31231620" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With &lt;i&gt;SH2D1A&lt;/i&gt;/&lt;i&gt;XIAP&lt;/i&gt; Hypomorphic Gene Variants.</a><span class="source">[Front Pediatr. 2019]</span><div class="brieflinkpop offscreen_noflow">Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With &lt;i&gt;SH2D1A&lt;/i&gt;/&lt;i&gt;XIAP&lt;/i&gt; Hypomorphic Gene Variants.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ishimura M, Eguchi K, Shiraishi A, Sonoda M, Azuma Y, Yamamoto H, Imadome KI, Ohga S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Front Pediatr. 2019; 7:183. Epub 2019 May 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22325832" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2.</a><span class="source">[Herpesviridae. 2012]</span><div class="brieflinkpop offscreen_noflow">Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Yang X, Wada T, Imadome K, Nishida N, Mukai T, Fujiwara M, Kawashima H, Kato F, Fujiwara S, Yachie A, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Herpesviridae. 2012 Feb 10; 3(1):1. Epub 2012 Feb 10.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301584" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Allenspach E, Rawlings DJ, Scharenberg AM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31754776" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic.</a><span class="source">[Eur J Pediatr. 2019]</span><div class="brieflinkpop offscreen_noflow">X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Xu T, Zhao Q, Li W, Chen X, Xue X, Chen Z, Du X, Bai X, Zhao Q, Zhou L, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Pediatr. 2019 Nov 21; . Epub 2019 Nov 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301357" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">WAS</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">WAS</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chandra S, Bronicki L, Nagaraj CB, Zhang K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301580" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301580" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041524dd21425a25fea4d3">Lymphoproliferative Disease, X-Linked - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Lymphoproliferative Disease, X-Linked - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:04:20-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE894E52E040A3E100000000056E0272&amp;ncbi_session=CE894E52E0415241_1390SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1406%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1406&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1406/&amp;ncbi_pagename=Lymphoproliferative Disease, X-Linked - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE894E52E0415241_1390SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>